478 related articles for article (PubMed ID: 21898376)
1. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
4. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
7. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
[TBL] [Abstract][Full Text] [Related]
10. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
11. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK; Halabi S; Sanford BL; Hahn O; Michaelson MD; Walsh MK; Feldman DR; Olencki T; Picus J; Small EJ; Dakhil S; George DJ; Morris MJ
J Clin Oncol; 2017 Feb; 35(6):591-597. PubMed ID: 28199818
[TBL] [Abstract][Full Text] [Related]
14. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience.
Ezz El Din M
Clin Genitourin Cancer; 2017 Jun; 15(3):e455-e462. PubMed ID: 28392154
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
[TBL] [Abstract][Full Text] [Related]
20. Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.
Castellano D; Maroto JP; Espinosa E; Grande E; Bolós MV; Llinares J; Esteban E; González Del Alba A; Climent MA; Arranz JA; Méndez MJ; Fernández Parra E; Antón-Aparicio L; Bayona C; Gallegos I; Gallardo E; Samaniego L; García Donas J
Expert Opin Drug Saf; 2018 Jun; 17(6):573-579. PubMed ID: 28535693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
